Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Five Launches Bring 2021 First-Time Offerings Total To 67
Executive Summary
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
You may also be interested in...
Swedish Biotech Developing Stem Cell Therapies From Amniotic Fluid
Swedish biotech Amniotics is developing a broad pipeline of unique stem cell therapeutics based on technology that is broadly applicable to major disease markets which should eventually draw the attention of big pharma players, its CEO tells Scrip.
Chinese Bioventures Grab $860m In Latest Public Listing, Financing Dash
Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.
Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia
Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.